Multiple Myeloma Research Center

Home Research Education Resources Support Group

 

Innovative Therapy Research Updates

Arsenic in Myeloma Doxil in MM Therapy DVd with Revimid Revimid Therapy DVd T Neovastat PhaseII Osteoprotegerin(OPG) Rituxan Temodar Velcade Procrit IL-2 ATRA GM-CSF in MM Peg L-Asparaginase GM-CSF

Home Up Next

 

The following are the Research Protocols for the different Management stages of Multiple Myeloma

 

Newly Diagnosed

  • Doxil, Vincristine, Decadron, and Thalidomide. This is a trial that evaluates the role of thalidomide in improving response rate as well as the quality of response to DVd
  • Doxil, Vincristine and Decadron (DVd) vs. VAD in newly diagnosed myeloma Phase III Trial in Newly Diagnosed Multiple Myeloma patients. this study is to confirm the results of the phase II DVd trial performed at our institutions


Refractory/Relapsed

Maintenance

  • GM-CSF Maintenance following VAD Treatment. A Phase II study
  • A Phase II efficacy, tolerability, and safety study of Vincristine, Doxorubicin, Dexamethasone, and SDZ PSC 833 therapy in-patients with VAD Refractory Multiple Myeloma. ( Closed, possible improvement in response rate)
  • High dose Intermittent Schedule ATRA Phase II trial to evaluating its role of in the Management of Multiple Myeloma. (Closed, responses were short lived, however resulted in disease stabilization for an average of 4 months)
  • IL-2 Maintenance Therapy Pilot study to evaluate following chemotherapy with VAD for multiple Myeloma. (Closed, awaiting data maturation)

Supportive Care

This page was last updated on 09/08/2003 05:51:25 PM

 
Home Up Arsenic in Myeloma Doxil in MM Therapy DVd with Revimid Revimid Therapy DVd T Neovastat PhaseII Osteoprotegerin(OPG) Rituxan Temodar Velcade Procrit IL-2 ATRA GM-CSF in MM Peg L-Asparaginase GM-CSF
Phone: 216-445-6830
Fax: 216-445-3434

Maps & Directions

 Cleveland Clinic Home  |   Contact Us  |   Disclaimer  |   Privacy Statement
 Cleveland Clinic 2005

Page Last Updated 09/08/2003 05:51:25 PM